Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease
May 15, 2024 07:30 ET
|
Enable Injections, Inc.
CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug...
Enable Injections Expands Strategic Partnership with Roche
May 07, 2024 07:30 ET
|
Enable Injections, Inc.
CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery device technology,...
Enable Injections Achieves ISO 13485:2016 Certification to Meet Mounting Demand for Drug-Delivery Device Combination Products
January 08, 2018 06:00 ET
|
Enable Injections, Inc.
CINCINNATI, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Enable Injections, Inc., developer of the advanced enFuse™ large volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has...
Enable Injections Completes Cincinnati Manufacturing Facility for On Body Delivery Systems
June 07, 2016 06:00 ET
|
Enable Injections, Inc.
SAN FRANCISCO, June 07, 2016 (GLOBE NEWSWIRE) -- Enable Injections Inc., the developer of wearable medical devices that enable easy, at-home self-administration of high volume injectable drugs and...